Replies to post #593890 on NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Are you talking about this SPORE trial, DCVax-L combo with Pembrolizumab, where both cohorts, Group A and Group B are both being treated with poly-ICLC as an in vivo maturation and activation agent?

https://clinicaltrials.gov/ct2/show/NCT04201873



Or, are you talking about the future DCVax-L combo trial, with Pembrolizumab and a CSF-1R inhibitor, where all patients will be treated with DCVax-L along with poly-ICLC as an in vivo maturation and activation agent: